MA-0204

Cas No.:	2095128-17-7
Chemical Name:	(3R)-3-Methyl-6-[2-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]imidazol-1-yl]methyl]phenoxy]hexanoic acid
Synonyms:	(R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid;(3R)-3-Methyl-6-[2-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]imidazol-1-yl]methyl]phenoxy]hexanoic ac;MA-0204
SMILES:	FC(OC1C([H])=C([H])C(=C([H])C=1[H])C1=NC([H])=C(C([H])([H])[H])N1C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1OC([H])([H])C([H])([H])C([H])([H])[C@@]([H])(C([H])([H])[H])C([H])([H])C(=O)O[H])(F)F
Formula:	C25N2O4F3H27
M.Wt:	476.4881
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	MA-0204 is a potent, highly selective and orally available peroxisome proliferator activated receptor δ (PPARδ) modulator with EC50s of 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively. Potential treatment for Duchene Muscular Dystrophy (DMD)[1].
Target:	PPARδ:0.4 nM (EC50, in human) PPARδ:7.9 nM (EC50, in mouse) PPARδ:10 nM (EC50, in rat)
In Vivo:	PPARδ (30, 100 mg/kg) increases target gene transcription in the muscle[1].
In Vitro:	MA-0204 is >10,000-fold selective for activation of PPARδ over PPARα and PPARγ receptors. MA-0204 exhibits high protein binding to mouse plasma, good permeability and low potential for efflux. C[1]. MA-0204 (1.2-12 nM) improves fatty acid oxidation in DMD patient muscle myoblasts mice[1]. MA-0204 (0.04-40 nM) engages target gene expression in DMD patient muscle myoblasts[1].
References:	[1]. Lagu B, et al. Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD). ACS Med Chem Lett. 2018 Jul 31;9(9):935-940.